Showing 4231-4240 of 4951 results for "".
- Study: Severe Psoriasis More Common in Menhttps://practicaldermatology.com/news/severe-psoriasis-more-common-in-men/2458235/Severe psoriasis predominantly affects men, according to a new study in the American Journal of Clinical Dermatology. In the study of 5,438 Swedish psoriasis patients, women had significantly (p<0.
- Education Credits Available: ABCs of Nitric Oxide in the Skinhttps://practicaldermatology.com/news/education-credits-available-abcs-of-nitric-oxide-in-the-skin/2458239/A free, online educational program intended to provide participants increased knowledge regarding the role of NO in maintaining a variety of physiologic processes has been launched. The program is directed by James Q. Del Rosso, DO. The program is also intended to address the correlation of
- AAD Throws Some Shade At 26 Schools With 2017 Shade Structure Grantshttps://practicaldermatology.com/news/aad-throws-some-shade-at-26-schools-with-2017-shade-structure-grants/2458245/The American Academy of Dermatology (AAD) awarded shade structure grants to 26 schools and non-profit organizations across the country. Since its launch in 2000, the AAD’s Shade Structure Grant Program has awarded 350 shade structure grants, which pr
- Dermalogica's Newest Add Targets Tired Eyeshttps://practicaldermatology.com/news/dermalogicas-newest-add-targets-tired-eyes/2458244/Dermalogica is launching their newest product – a two-in-one eye masque that targets tired eyes. The Stress Positive Eye Lift officially launches in early April 2017. Put on with a cooling massage applicator, this masque reduces the a
- RepliCel's Baldness Cure Performs Well In First In-Human Trialhttps://practicaldermatology.com/news/replicels-baldness-cure-performs-well-in-first-in-human-trial/2458246/The first in-human study of RepliCel Life Sciences Inc’s investigational baldness cure, RCH-01, confirms the therapy’s safety and demonstrates strong efficacy signals, the company reports. The autologous cell therapy involves culturing a person’s own dermal sheath cup ce
- A “C” Change: Introducing Exuviance's New Vitamin C Serum Capsuleshttps://practicaldermatology.com/news/a-c-change-introducing-exuviances-new-vitamin-c-serum-capsules/2458250/Coming this summer, Exuviance’s AF Vitamin C20 serum capsules promise maximum delivery of actives. Unlike many existing products, Exuviance AF Vitamin C20 Serum comes in capsule form. Other types of packaging expose vitamin C to light, air, o
- New Biomarker May Help Guide Metastatic Melanoma Treatment Decisionshttps://practicaldermatology.com/news/new-biomarker-may-guide-metastatic-melanoma-treatment-decisions/2458253/Measuring levels of Bim—a protein made by cancer-fighting T cells—via a simple blood draw can help doctors predict which metastatic melanoma patients would benefit from anti-PD-1 checkpoint blockade. Such personalized medicine can help eliminate some of the trial and error ass
- New Research Closes In On Personalized AD Therapyhttps://practicaldermatology.com/news/new-research-closes-in-on-personalized-therapy-for-ad/2458254/New research on skin lipids may pave the way toward personalized therapies for atopic dermatitis. Researchers can now identify the precise lipids found in the skin of people who have atopic dermatitis, and compare them to people with healthy skin. Here’s how: A type of tape can pull
- Rare Disease Breakthrough? New Treatment May Reduce Blistering in EBShttps://practicaldermatology.com/news/rare-disease-breakthrough-new-treatment-may-reduce-blistering-in-ebs/2458255/In a possible breakthrough in the treatment of epidermolysis bullosa simplex (EBS), Diacerein 1% ointment reduced blistering in patients with this rare genetic connective tissue disorder. The new findings were presented in a late-breaker session at the American Academy of Dermatology Annu
- Mosquito Virus Expert Discusses a Promising New Drug For Zikahttps://practicaldermatology.com/news/mosquito-virus-expert-discusses-a-promising-new-drug-for-zika/2458257/Thomas Voss, PhD, a world-renowned leader in infectious disease research, and his team, say there are two strategies for developing a defense program against Zika infection: prevention, achieved by developing an effective vaccine and vaccination program or the development of a drug that can kill